Also called
ICD-10
Specialty
Onset
Reviewed
-
OverviewOverview
-
Etiology & Risk FactorsEtiology & Risk Factors
-
PathophysiologyPathophysiology
-
Clinical PresentationClinical Presentation
-
History TakingHistory Taking
-
Physical ExaminationPhysical Examination
-
InvestigationsInvestigations
-
DiagnosisDiagnosis
-
ManagementManagement
-
ComplicationsComplications
-
PrognosisPrognosis
-
Key Points / Clinical PearlsKey Points / Clinical Pearls
Overview
Hemophilia A is caused by factor VIII deficiency, while Hemophilia B is caused by factor IX deficiency. Both are usually X-linked recessive disorders, so they predominantly affect males. The severity depends on the residual clotting factor activity.
Etiology & Risk Factors
-Etiology
Hemophilia A
Caused by mutations in the F8 gene, resulting in reduced or absent factor VIII activity.
Hemophilia B
Caused by mutations in the F9 gene, resulting in reduced or absent factor IX activity.
Inheritance
Both are usually:
X-linked recessive
Mainly affect males
Females may be carriers
Rarely, females can have clinically significant disease
-Risk Factors
Family history
Maternal carrier status
Male sex
De novo mutation
Consanguinity may be relevant in rare familial cases
Pathophysiology
Factor VIII or IX deficiency → impaired intrinsic coagulation pathway → reduced activation of factor X → reduced thrombin generation → inadequate fibrin formation → defective secondary hemostasis → prolonged bleeding and recurrent bleeding into joints, muscles, and deep tissues.
Clinical Presentation
-Symptoms
Easy bruising
Prolonged bleeding after injury
Prolonged bleeding after surgery
Recurrent joint bleeding
Muscle hematomas
Nosebleeds
Oral bleeding
Hematuria
Gastrointestinal bleeding
Hemarthrosis
Commonly affects:
Knees
Ankles
Elbows
Repeated hemarthroses can cause chronic hemophilic arthropathy.
-Severe Disease
Severe hemophilia may present during infancy or early childhood with:
Spontaneous bleeding
Joint bleeding
Muscle hematomas
Intracranial hemorrhage
History Taking
-Ask about:
- Previous bleeding episodes
- Joint swelling or pain
- Muscle hematomas
- Prolonged bleeding after dental procedures
- Surgical bleeding
- Bleeding after circumcision
- Intracranial bleeding
- Hematuria
- Family history
- Maternal carrier status
- Previous factor replacement
- Inhibitor development
Physical Examination
-General Examination
Look for:
Pallor
Bruising
Signs of anemia
-Joint Examination
Assess for:
Swelling
Warmth
Tenderness
Reduced range of motion
Chronic joint deformity
Common joints:
Knee
Ankle
Elbow
-Muscle Examination
Look for:
Muscle swelling
Tenderness
Reduced movement
Signs of compartment syndrome
-Neurological Examination
Assess urgently for:
Headache
Altered consciousness
Focal neurological deficits
Signs of intracranial hemorrhage
Investigations
-Complete Blood Count
Usually:
Platelet count: normal
Hemoglobin may be reduced if significant bleeding has occurred
PT
Usually: Normal
aPTT Typically: Prolonged
Mixing Study
A prolonged aPTT that corrects with normal plasma supports a clotting factor deficiency.
Failure to correct suggests an inhibitor.
Factor Assays
Low factor VIII → Hemophilia A
Low factor IX → Hemophilia B
Inhibitor Testing
Patients receiving repeated factor replacement may develop factor VIII or IX inhibitors.
-The Bethesda assay can quantify inhibitor levels.
-Genetic Testing
Can identify the causative mutation and is useful for:
Confirming diagnosis
Carrier testing
Family counseling
Prenatal diagnosis
Diagnosis
Diagnosis is based on:
- Compatible bleeding history
- Family history
- Prolonged aPTT
- Normal PT
- Normal platelet count
- Reduced factor VIII or IX activity
- Genetic testing when required
Management
1. Factor Replacement
Hemophilia A
Replace factor VIII.
Options include:
Recombinant factor VIII
Extended half-life factor VIII preparations
Hemophilia B
Replace factor IX.
Options include:
Recombinant factor IX
Extended half-life factor IX preparations
Factor replacement is used for:
Acute bleeding
Surgical procedures
Trauma
Prevention of recurrent bleeding
2. Emicizumab
Used primarily for Hemophilia A, particularly for routine prophylaxis.
It is a bispecific antibody that mimics the function of factor VIII in the coagulation pathway.
3. Desmopressin
Useful in selected patients with:
Mild Hemophilia A
It increases endogenous factor VIII and von Willebrand factor.
It is not useful for Hemophilia B.
4. Antifibrinolytic Therapy
Examples:
Tranexamic acid
Aminocaproic acid
Particularly useful for:
Dental procedures
Oral bleeding
Mucosal bleeding
5. Inhibitors
If significant factor inhibitors develop, management may include:
Bypassing agents
Emicizumab for Hemophilia A
Immune tolerance induction in selected patients
Complications
- Recurrent hemarthrosis
- Chronic hemophilic arthropathy
- Muscle hematomas
- Intracranial hemorrhage
- Gastrointestinal bleeding
- Urinary tract bleeding
- Compartment syndrome
- Inhibitor development
- Transfusion-related complications in older treatment eras
- Chronic pain
- Disability
Prognosis
With modern factor replacement, prophylaxis, and comprehensive specialist care, people with hemophilia can have near-normal life expectancy and good quality of life. The major long-term concerns are recurrent bleeding, joint damage, and development of factor inhibitors.
Key Points / Clinical Pearls
- Hemophilia A = factor VIII deficiency.
- Hemophilia B = factor IX deficiency.
- Both are usually X-linked recessive.
- They cause deep tissue bleeding and hemarthrosis.
- PT is normal.
- aPTT is prolonged.
- Platelet count is usually normal.
- Factor assays confirm the deficient clotting factor.
- Hemophilia A may respond to desmopressin when mild.
- Emicizumab is an important prophylactic option for Hemophilia A.
- Hemophilia B is treated with factor IX replacement.
- Inhibitors are an important complication of factor replacement.
- Early treatment of bleeding helps prevent permanent joint damage.
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1-158. World Federation of Hemophilia Guidelines .
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. World Federation of Hemophilia .
- National Heart, Lung, and Blood Institute (NIH). Hemophilia .
- National Library of Medicine (NIH). Hemophilia A .
- National Library of Medicine (NIH). Hemophilia B .
Practice Hemophilia A & B questions
Lock in what you just read with exam-style MCQs and active-recall flashcards from Saturn Medic.